You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Article metrics

Article menu

Download PDFPDF

XML
Interstitial lung disease
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

 

Online download statistics by month:

Online download statistics by month: May 2019 to August 2024

AbstractFullPdf
May 2019449458287
Jun 2019287313146
Jul 201917116075
Aug 201915113568
Sep 201916513973
Oct 201918015965
Nov 201917315065
Dec 201920618677
Jan 202021319767
Feb 202024524378
Mar 202017417445
Apr 202015115144
May 202012712739
Jun 202013613647
Jul 20201059334
Aug 2020828029
Sep 202018517143
Oct 202015814746
Nov 202013112048
Dec 20201029033
Jan 202113412753
Feb 202116014874
Mar 2021898231
Apr 2021887835
May 2021757115
Jun 2021777223
Jul 2021625523
Aug 2021635921
Sep 2021706328
Oct 2021786945
Nov 2021706230
Dec 2021615627
Jan 2022837630
Feb 2022554722
Mar 2022888536
Apr 202219418933
May 2022747630
Jun 2022727218
Jul 2022767826
Aug 2022756521
Sep 2022917824
Oct 2022545418
Nov 2022715923
Dec 2022434517
Jan 2023615325
Feb 20231009531
Mar 2023706423
Apr 2023464627
May 2023676030
Jun 2023434213
Jul 2023786934
Aug 2023726317
Sep 20231059430
Oct 202320019927
Nov 202346946620
Dec 202312612429
Jan 202485857
Feb 2024656325
Mar 2024898429
Apr 2024807637
May 2024555415
Jun 2024484121
Jul 2024464220
Aug 2024706425
Total756971792597